Wockhardt's stock soared 20% as Zaynich antibiotic treated a US cancer patient with Pseudomonas infection at Children's Hospital of Orange County. The drug's success enabled chemotherapy, highlighting its potential impact on cancer deaths and Wockhardt's financial outlook.
